Skip To Main Content

Downloadable resources

Resources for you and your loved ones

About CABLIVI

Download any of the PDFs below to keep important information about CABLIVI and aTTP/iTTP* on hand.

Taking CABLIVI

Download the PDF below so you’ll always have easy access to information about taking CABLIVI.

Talking with your care team

Download any of the PDFs below to help guide your conversations with your care team.

CABLIVI, in combination with PEX and immunosuppression, can help you take on aTTP/iTTP with confidence

 

SEE HOW

 

Videos about CABLIVI—from people’s stories to how to take therapy at home—are available to you
 

 

WATCH NOW

 

*aTTP is also known as iTTP. You and your healthcare team can use either term.
This card is not meant to take the place of a medical identification bracelet or any other identification item suggested by your healthcare provider. You should speak with your healthcare provider about any additional requirements that would be helpful to identify that you have aTTP/iTTP.
aTTP/iTTP=acquired/immune-mediated thrombotic thrombocytopenic purpura.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
 

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

Talk to your doctor before scheduling any surgery, medical or dental procedure.
 

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
 

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.